Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NVE CORP /NEW/nvec · Entity 5507 | Director | August 06, 2020 | August 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NVE CORP /NEW/
Report date August 06, 2020 · Filed August 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.24 · Expires 2030-08-06 | Direct | 7,000 |
Reported balance
After 2020-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-06 · Grant · Acquired 1,000 · Balance 7,000 F1: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SURMODICS INC
Report date November 19, 2025 · Filed November 19, 2025
Section 16 reporting ended · disclosed 2025-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Disposition to issuer · Disposed 192,056 · Balance 0 F1: Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs. F2: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.63 · Expires 2025-11-27 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-19 · Disposition to issuer · Disposed 45,073 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.00 · Expires 2026-11-26 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-19 · Disposition to issuer · Disposed 62,674 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.93 · Expires 2028-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-19 · Disposition to issuer · Disposed 73,349 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.13 · Expires 2029-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-19 · Disposition to issuer · Disposed 84,669 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.64 · Expires 2030-12-04 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-19 · Disposition to issuer · Disposed 89,127 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.44 · Expires 2027-11-30 | Direct | 0 |
Reported balance
After 2025-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-19 · Disposition to issuer · Disposed 74,515 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs.
F2: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock.
F3: Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2018 Filed Sep 6, 2018 16:43 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 1,300 | $80.16 | $104,213.07 |
DisclosureSEC source: 0001209191-18-049847 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,279 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F4 · price: Reflects the weighted average price of 1,300 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on September 4, 2018 with sale prices ranging from $79.95 to $80.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:43 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 3,700 | $79.40 | $293,782.59 |
DisclosureSEC source: 0001209191-18-049847 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,579 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 3,700 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on September 4, 2018 with sale prices ranging from $78.90 to $79.90 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 693 shares acquired through the Employee Stock Purchase Plan for the phase ending August 31, 2018. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 20:49 UTC | NVE CORP /NEW/ nvec · Entity 5507 | GrantNon-Qualified Stock Option · Derivative | 1,000 | $0.00 Strike: $107.86 | $0.00 |
DisclosureSEC source: 0000724910-18-000028 · primary_doc.xml · derivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 1,000 shares Expires 2028-08-02 F1 · shares: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 15:57 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $58.93 | $294,627.00 |
DisclosureSEC source: 0001209191-18-044908 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,586 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 1, 2018 with sale prices ranging from $58.50 to $60.03 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:38 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $54.48 | $272,400.00 |
DisclosureSEC source: 0001209191-18-041662 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,586 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2018. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on July 2, 2018 with sale prices ranging from $54.25 to $55.00 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:06 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 27,173 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030045 · doc4.xml · derivative · entry 5 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,174 Underlying: Common Stock · 27,173 shares Expires 2022-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the December 17, 2015 grant date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:06 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,932 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001209191-18-030045 · doc4.xml · derivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,311 Underlying: Common Stock · 30,932 shares Expires 2021-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the December 2, 2014 grant date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:06 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 41,077 | $44.80 | $1,840,249.60 |
DisclosureSEC source: 0001209191-18-030045 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,586 Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:06 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionCommon Stock | 27,173 | $20.25 | $550,253.25 |
DisclosureSEC source: 0001209191-18-030045 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2018 Filed May 14, 2018 19:06 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionCommon Stock | 30,932 | $21.03 | $650,499.96 |
DisclosureSEC source: 0001209191-18-030045 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 15:41 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 36,434 | $0.00 Strike: $22.58 | $0.00 |
DisclosureSEC source: 0001209191-18-021887 · doc4.xml · derivative · entry 5 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,434 shares Expires 2020-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 15:41 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 38,325 | $0.00 Strike: $20.37 | $0.00 |
DisclosureSEC source: 0001209191-18-021887 · doc4.xml · derivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,325 shares Expires 2019-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 15:41 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 56,748 | $38.50 | $2,184,798.00 |
DisclosureSEC source: 0001209191-18-021887 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,558 Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 15:41 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionCommon Stock | 36,434 | $22.58 | $822,679.72 |
DisclosureSEC source: 0001209191-18-021887 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 15:41 UTC | SURMODICS INC SRDX · Entity 72915 | Exercise / conversionCommon Stock | 38,325 | $20.37 | $780,680.25 |
DisclosureSEC source: 0001209191-18-021887 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 405 shares acquired through the Employee Stock Purchase Plan for the phase ending February 28, 2018. Read SEC document |
| November 30, 2017 Filed Nov 30, 2017 20:25 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 1,141 | $33.10 | $37,767.10 |
DisclosureSEC source: 0001209191-17-063116 · doc4.xml · nonDerivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,142 Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 20:25 UTC | SURMODICS INC SRDX · Entity 72915 | GrantEmployee Stock Option (right to buy) · Derivative | 61,017 | $0.00 Strike: $33.20 | $0.00 |
DisclosureSEC source: 0001209191-17-063116 · doc4.xml · derivative · entry 5 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,017 Underlying: Common Stock · 61,017 shares Expires 2024-11-28 F4 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the November 28, 2017 grant date. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 20:25 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 9,088 | $33.20 | $301,721.60 |
DisclosureSEC source: 0001209191-17-063116 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,283 F3 · shares: Shares withheld to satisfy taxes incident to vesting of performance share award. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 20:25 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 18,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-063116 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,371 F2 · shares: Shares issued in connection with the vesting of a performance share award under long-term incentive plan based on performance during three-year period ended September 30, 2017. Read SEC document |
| November 28, 2017 Filed Nov 30, 2017 20:25 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 12,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-063116 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,518 F1 · balance_after: Includes 760 shares acquired through the Employee Stock Purchase Plan for the phase ending August 31, 2017. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 16:56 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $25.75 | $128,750.00 |
DisclosureSEC source: 0001209191-17-048280 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,807 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:35 UTC | NVE CORP /NEW/ nvec · Entity 5507 | GrantNon-Qualified Stock Option · Derivative | 1,000 | $0.00 Strike: $76.13 | $0.00 |
DisclosureSEC source: 0000724910-17-000035 · primary_doc.xml · derivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,000 shares Expires 2027-08-03 F1 · shares: Option granted automatically on Mr. Maharaj's reelection to NVE's Board of Directors Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 17:25 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $28.03 | $140,157.50 |
DisclosureSEC source: 0001209191-17-044164 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,807 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on July 3, 2017 with sale prices ranging from $27.85 to $28.45 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 16:34 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 2,702 | $25.09 | $67,791.29 |
DisclosureSEC source: 0001209191-17-038309 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,807 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. F2 · price: Reflects the weighted average price of 2,702 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on June 5, 2017, with sale prices ranging from $25.00 to $25.65 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:26 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 584 | $25.00 | $14,600.00 |
DisclosureSEC source: 0001209191-17-025767 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,509 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. F2 · balance_after: Includes 485 shares acquired through the Employee Stock Purchase Plan for the phase ending February 28, 2017. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:30 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $25.05 | $125,250.00 |
DisclosureSEC source: 0001209191-17-002098 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,608 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 18:44 UTC | SURMODICS INC SRDX · Entity 72915 | GrantEmployee Stock Option (right to buy) · Derivative | 44,779 | $0.00 Strike: $23.95 | $0.00 |
DisclosureSEC source: 0001209191-16-153162 · doc4.xml · derivative · entry 4 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,779 Underlying: Common Stock · 44,779 shares Expires 2023-11-30 F3 · derivative.exercise_date: The award vests in four equal installments on each of the first four anniversaries of the November 30, 2016 grant date. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 18:44 UTC | SURMODICS INC SRDX · Entity 72915 | Tax withholdingCommon Stock | 6,797 | $23.95 | $162,788.15 |
DisclosureSEC source: 0001209191-16-153162 · doc4.xml · nonDerivative · entry 3 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,608 F2 · shares: Shares withheld to satisfy taxes incident to vesting of performance share award. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 18:44 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 14,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153162 · doc4.xml · nonDerivative · entry 2 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,405 F1 · shares: Performance shares awarded under long-term incentive plan based on performance during three-year period ended September 30, 2016. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 18:44 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 7,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153162 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,305 Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 18:23 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $25.22 | $126,115.50 |
DisclosureSEC source: 0001209191-16-149149 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,207 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on November 7, 2016 with sale prices ranging from $25.00 to $25.60 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:55 UTC | SURMODICS INC SRDX · Entity 72915 | SaleCommon Stock | 5,000 | $29.55 | $147,770.00 |
DisclosureSEC source: 0001209191-16-145034 · doc4.xml · nonDerivative · entry 1 Maharaj Gary R · CIK 0001508798 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,207 F1 · kind: Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2016. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on October 3, 2016 with sale prices ranging from $29.12 to $29.85 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 898 shares acquired through the Employee Stock Purchase Plan for the phase ending August 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.